Natural Killer/T-Cell Lymphoma
Conditions
Interventions
Case series:concurrent chemoradiotherapy followed by long-acting aspargase (pegylated aspargase, PEG-ASP) combined with Ifosfamide,dexamethasone and Etoposide (PIDE) treatment
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old, ECOG performance status of 0, 1, or 2, Life expectancy of >12 weeks; 2. All patents are diagnosed as stage I/II Nasal Natural Killer/T-Cell Lymphoma by pathology and PET-CT/CT. All patients did not receive other treatment; 3. Adequate hematologic and hepatic-renal function: Hemoglobin >=9 g/dl, Absolute neutrophil count >=1.5*10^9/L, Platelet count >=100*10^9/L, ALT 1.5cm in its largest dimension on CT scan; 5. Adequate cardiopulmonary function, no other serious disease; 6. The Pregnancy test of blood or urine is negative for women of reproductive potential. All patients agree to use adequate methods of contraception during the treatment period and until >= 12 months after the last chemotherapy; 7. Ability and willingness to comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1. Patients received other treatment such as chemotherapy or radiotherapy; 2. Refuse to provide the blood sample; 3. History of severe allergic or anaphylactic reactions to any drugs including the protocol; 4. All patients of reproductive potential refuse to use adequate methods of contraception during the treatment period and until >12 months after the last chemotherapy; 5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease, uncontrolled diabetes mellitus, pulmonary disease or severe hepatic and renal dysfunction; 6. Serious infections; 7. Contraindications of radiotherapy and chemotherapy; 8. History of other malignancy; 9. Mental disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Overall survival;Response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response;partial response;Median survival time; | — |
Countries
China
Contacts
Public ContactGang Wu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed